Combination docetaxel (Taxotere), fluorouracil, and leucovorin (TFL), as first-line chemotherapy in advanced gastric cancer: A Hellenic Cooperative Oncology Group phase II study

被引：7

作者：

Papakostas P. ^{[1
]}

Tsavdaridis D. ^{[2
]}

Kosmidis P. ^{[3
]}

Kalofonos H.P. ^{[4
]}

Sakantamis A. ^{[5
]}

Janinis D. ^{[6
]}

Skarlos D. ^{[7
]}

Bafaloukos D. ^{[8
]}

Bamias A. ^{[9
]}

Xiros N. ^{[10
]}

Fountzilas G. ^{[11
]}

机构：

[1] Oncology Department, Hippokration General Hospital, Athens, 108, Vas.Sofias Avenue

[2] IKA Hospital, Thessaloniki

[3] Hygeia Hospital, Athens

[4] Patras University Hospital, Patras

[5] Hippokration Hospital, Thessaloniki

[6] Agii Anargiri Cancer Hospital, Athens

[7] Henry Dynan Hospital, Athens

[8] Metropolitan Medical Center, Athens

[9] Ioannina University Hospital, Ioannina

[10] University General Hospital Attikon, Athens

[11] Papageorgiou Hospital, Aristotle University of Thessaloniki, School of Medicine, Thessaloniki

来源：

Gastric Cancer | 2006年 / 9卷 / 1期

关键词：

Docetaxel; Fluorouracil; Gastric cancer;

D O I：

10.1007/s10120-005-0353-4

中图分类号：

学科分类号：

摘要：

Background. We assessed the efficacy and safety profile of a docetaxel (Taxotere; Sanofi-Aventis, France), fluorouracil (FU), and leucovorin (LV) combination (TFL), as first-line chemotherapy in patients with advanced gastric cancer. Methods. Fifty-eight patients with advanced gastric cancer were entered in this phase II study. The chemotherapy regimen (TFL) was administered in an outpatient setting as follows: docetaxel 7mg/m2 on day 1 and FU 50mg/m2 and LV 30mg/m2 on days 1 to 3, every 3 weeks for six cycles. Results. On an intent-to-treat basis, 4 complete (7%) and 11 partial responses (19%) were observed, with an objective overall response rate of 26%; in addition, 22 patients (38%) had stable and 15 (26%) had progressive disease. For 6 (10%) patients, response could not be evaluated. Responses were noted at all metastatic sites. With a median follow-up of 55 months, median survival was 9 months; median time to progression, 5.9 months; and median duration of response, 10 months. Toxicity was manageable and no toxic death was reported. Neutropenia was the most frequent severe toxicity and occurred in 30% of the patients. The main non-hematologic toxicities were alopecia (76%), diarrhea (30%), and stomatitis (30%). Conclusion. The results of this phase II study seem to indicate that the TFL regimen has moderate activity in patients with advanced gastric cancer, with acceptable toxicity. © 2006 by International and Japanese Gastric Cancer Association.

引用

页码：26 / 31

页数：5

共 16 条

[1]

Report 1998: A Vision for All, (1998)

[2]

Akoh A.J., McIntyre I.M.C., Improving survival in gastric cancer: Review of 5-year survival rates in English-language publications from 1970, Br J Surg, 79, pp. 293-9, (1992)

[3]

Pyrhonen S., Kuitunen T., Nyandoto P., Kouri M., Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer, Br J Cancer, 71, pp. 587-91, (1995)

[4]

Cullinan S.A., Moertel C.G., Fleming T.R., Rubin J.R., Krook J.E., Everson L.K., Et al., A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin and mitomycin, JAMA, 253, pp. 2061-7, (1985)

[5]

Wils J., The treatment of advanced gastric cancer, Semin Oncol, 23, pp. 397-406, (1996)

[6]

Webb A., Cunningham D., Scarffe J.H., Harper P., Norman A., Joffe J.K., Et al., Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer, J Clin Oncol, 15, pp. 261-7, (1997)

[7]

Kelsen D., Atiq O.T., Saltz L., Niedzwiecki D., Ginn D., Chapman D., Et al., FAMTX versus etoposide, doxorubicin and cisplatin. a randomized trial in gastric cancer, J Clin Oncol, 10, pp. 541-8, (1992)

[8]

Sulkes A., Smyth J., Sessa C., Dirix L.Y., Vermorken J.B., Kaye S., Et al., Docetaxel (Taxotere) in advanced gastric cancer: Results of a phase II clinical trial. EORTC Early Clinical Trials Group, Br J Cancer, 70, pp. 380-3, (1994)

[9]

Mai M., Sakata Y., Kanamaru R., Kurihara M., Suminaga M., Ota J., Et al., A late phase II clinical study of RP 56976 (docetaxel) in advanced or recurrent gastric cancer, Gan to Kagaku Ryoho (Jpn J Cancer Chemother), 26, pp. 487-96, (1999)

[10]

Louvet C., De Gramont A., Demuynck B., Nordlinger B., Maisani J.E., Lagadec B., Et al., High-dose folinic acid, 5-fluorouracil bolus and continuous infusion in poor-prognosis patients with advanced measurable gastric cancer, Ann Oncol, 2, pp. 231-3, (1991)

← 1 2 →